Atrial Fibrillation, a Treatable Disease? by J.H. KingmaAtrial Fibrillation, a Treatable Disease? by J.H. Kingma

Atrial Fibrillation, a Treatable Disease?

byJ.H. KingmaEditorN.M. van Hemel, K.J. Lie

Paperback | October 29, 2012

Pricing and Purchase Info

$159.31 online 
$191.95 list price save 17%
Earn 797 plum® points

Prices and offers may vary in store

Quantity:

In stock online

Ships free on orders over $25

Not available in stores

about

The attack of atrial fibrillation experienced by President Bush of the United States attracted more attention from the general public to atrial fibrillation than ever before. Also, there is a growing body of knowledge of the pathophysiologic mechanism, the pathology and epidemiology, and especially of the thrombo-embolic complications of this arrhythmia, which is responsible for a renewed interest of the clinician in this very common human arrhythmia. These new perspectives on atrial fibrillation were presented during a conference on `Atrial Fibrillation, a Treatable Disease?', organized on May 7, 1992, in Amsterdam, the Netherlands. Atrial fibrillation is not the prerogative of the cardiologist only. Many practitioners from other areas in health care, in particular general physicians, internists and neurologists, are faced with this arrhythmia and its untoward consequences. This book bridges the gap between theory, experiment and the clinic. Emphasis is therefore on the selection of the optimal approach, including pharmacotherapy, catheter ablation, pacemaker and surgical therapy, based on the current scientific insights in the mechanism and prevention of atrial fibrillation.
Title:Atrial Fibrillation, a Treatable Disease?Format:PaperbackDimensions:304 pages, 24 × 16 × 0.07 inPublished:October 29, 2012Publisher:Springer NatureLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:9401048010

ISBN - 13:9789401048019

Reviews

Table of Contents

Foreword. Preface. Section 1: Concepts and Clinics of Atrial Fibrillation. 1. From Experiment to Therapeutic Innovation in Atrial Fibrillation and Flutter. 2. Atrial Functional Anatomy. 3. The Pathology of Drug Resistant Lone Atrial Fibrillation in Eleven Surgically Treated Patients. 4. Termination of Atrial Fibrillation by Classic Antiarrhythmic Drugs, a Paradox? 5. Characteristics of Patients with Chronic Atrial Fibrillation and the Prediction of Successful DC Electrical Cardioversion. Section 2: Recent Advances in the Treatment of Paroxysmal Atrial Fibrillation and Flutter. 6. Pharmacological Cardioversion of Paroxysmal Atrial Fibrillation or Atrial Flutter to Sinus Rhythm. 7. Drugs after Cardioversion to Prevent Relapses of Chronic Atrial Fibrillation or Flutter. 8. Episodic Treatment of Paroxysmal Atrial Fibrillation. 9. An AICD for Atrial Fibrillation? 10. The 'Corridor' Operation as an Alternative in the Treatment of Atrial Fibrillation. Section 3: Why Aggressive Therapy in Atrial Fibrillation? 11. Tachycardiomyopathy in Patients with Supraventricular Tachycardia. 12. Sinus Rhythm, the Autonomic Nervous System, and Quality of Life. 13. Atrial Tachyarrhythmias following Coronary Bypass Surgery: Sympathetic Mechanisms. 14. Management of Paroxysmal Atrial Fibrillation and Atrial Flutter shortly after Coronary Artery Bypass Graft Surgery. 15. Risk and Prevention of Embolism in Atrial Fibrillation. 16. Value of Left Atrial Appendage Flow Velocitiesin Patients with Nonrheumatic Atrial Fibrillation and Systemic Embolism. 17. Management of Atrial Fibrillation: From Palliation to Intervention.Index.